Healthcare >> CEO Interviews >> November 1, 1999
BioTime, Inc. is a biotechnology R&D company, with a pipeline of
products that it is developing. It has three exciting products with huge
growth potential. President & COO Ronald S. Barkin says that Hextend, a
plasma volume expander, was approved earlier this year, and is being
marketed by Abbott Laboratories. A second plasma expander called
Pentalyte will begin clinical trials with the FDA before the end of the
year. HetaCool, the low temperature product that the company originally
developed, has proved effective in animal studies and hopefully interim
human clinical trials will shortly commence. The home runs he is
looking at are going to be in the company's product sales, its licensing
agreements overseas, and in bringing other products to market. He is
very confident that the company will have an excellent bottomline and
that ultimately the stock price will reflect that. Profile
Inc., the company's history, products, activities, customers, those
kinds of things.
Mr. Barkin: BioTime was formed in
